सेनोर्स फार्मास्यूटिकल्स शेयर की कीमत

फार्मास्यूटिकल्स कंपनी सेनोर्स फार्मास्यूटिकल्स ने Q4FY26 और FY26 के परिणामों की घोषणा की, समेकित फाइनेंशियल परिणाम: संचालन से राजस्व: Q4FY26: ₹ 175.19 करोड़ रहा, जिसमें QoQ में 2.48% की वृद्धि (Q3FY26 में ₹ 170.95 करोड़ से) और YoY में 53.39% की वृद्धि दर्ज की गई (Q4FY25 में ₹ 114.21 करोड़ से). FY26: में ₹632.63 करोड़ की रिपोर्ट हुई, जो FY25 में ₹396.25 करोड़ की तुलना में 59.65% की YoY वृद्धि का संकेत देती है. Total Income: Q4FY26: Reached Rs 182.86 crore, registering a QoQ increase of 2.53% (from Rs 178.34 crore) and a YoY growth of 45.15% (from Rs 125.98 crore). (ध्यान दें: मीडिया रिलीज़ में अन्य ऑपरेटिंग इनकम सहित ₹190 करोड़ की कुल इनकम की जानकारी दी गई है). FY26: Reached Rs 679.69 crore, marking a YoY increase of 62.79% from Rs 417.51 crore. (ध्यान दें: मीडिया रिलीज़ में अन्य ऑपरेटिंग इनकम सहित ₹664 करोड़ की कुल इनकम की जानकारी दी गई है). EBITDA: Q4FY26: Achieved Rs 62 crore, jumping 219% YoY. FY26: Recorded at Rs 200 crore, reflecting a 114% YoY growth. Profit Before Tax (PBT): Q4FY26: Stood at Rs 47.40 crore, up by 6.28% QoQ (from Rs 44.60 crore) and a substantial 129.21% YoY (from Rs 20.68 crore). FY26: Reached Rs 159.10 crore, growing 125.45% YoY compared to Rs 70.57 वित्त वर्ष 25 में करोड़. Net Profit After Tax (PAT): Q4FY26: Reported at Rs 36.67 crore (highlighted as Rs 37 crore in the media release), up 9.20% QoQ (from Rs 33.58 crore) and 104.06% YoY (from Rs 17.97 crore). FY26: Surged to Rs 121.53 crore (highlighted as Rs 122 crore in the media release), reflecting a 108.31% YoY growth against Rs 58.34 crore in FY25. Standalone Financial Highlights: Revenue from Operations: Q4FY26: Stood at Rs 36.81 crore, reflecting a massive QoQ increase of 46.36% (from Rs 25.15 crore) and YoY jump of 210.37% (from Rs 11.86 crore). FY26: Reported at Rs 106.09 crore, marking a 175.27% YoY growth from Rs 38.54 crore. कुल इनकम: Q4FY26: बढ़कर ₹ 59.00 करोड़, 53.09% QoQ (₹ 38.54 करोड़ से) और 179.49% तक पहुंच गया YoY (₹ 21.11 करोड़ से). FY26: Jumped to Rs 172.44 crore, growing 184.88% YoY from Rs 60.53 crore. Profit Before Tax (PBT): Q4FY26: Stood at Rs 12.69 crore, surging 260.51% QoQ (from Rs 3.52 crore) and 337.59% YoY (₹ 2.90 करोड़ से). FY26: Skyrocketed to Rs 27.46 crore, recording a 437.38% YoY growth from Rs 5.11 crore. Net Profit After Tax (PAT): Q4FY26: Reached Rs 8.48 crore, up 220.00% QoQ (from Rs 2.65 crore) and 319.80% YoY (₹ 2.02 करोड़ से). FY26: Reported at Rs 20.25 crore, achieving a 448.78% वार्षिक वृद्धि ₹ 3.69 करोड़ से. Business & Segmental Highlights: Segment-wise Performance: Regulated Markets: Revenue in Q4FY26 stood at Rs 117.8 crore (up 169.0% वाय). For FY26, it recorded Rs 427.4 crore (growing by 90.6% YoY). Emerging Markets: Revenue reached Rs 49.5 crore in Q4FY26 (up 5.7% YoY). In FY26, revenue stood at Rs 148.6 crore, expanding by 13.1% YoY. The segment reported an EBITDA margin of ~12% for FY26 and is now cash flow positive. Branded Generics: Revenue achieved Rs 9.4 crore in Q4FY26 (up 132.4% YoY). The segment showcased exceptional growth in FY26, increasing ~385.3% YoY to Rs 40.0 crore. Other Operating Income: Stood at Rs 13.1 crore in Q4FY26 (-33.6% YoY) and Rs 48.1 crore for FY26 (+27.3% वाय). Swapnil Shah, Managing Director, Senores Pharmaceuticals, said: “We have delivered a robust performance across segments in FY26, driven by operational discipline, consistent execution, and strong momentum in key growth areas despite an uncertain operating environment. In the Regulated Markets, our approved ANDA portfolio has more than doubled during the year, increasing from 26 ANDAs as of March 2025 to 51 ANDAs as of March 2026, reflecting the scale and pace of our execution. Out of these, 30 approved ANDAs are yet to be commercialized. इसके अलावा, हमारे पास 27 और अणु हैं, जिनमें विकास के विभिन्न चरणों में 65+ विशिष्ट शक्तियां शामिल हैं. This gives us a strong pipeline of products which are expected to be rolled out over the coming years. We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharmaceuticals. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth. We have commenced product rollouts from the Apnar facility, with initial revenues starting in Q4FY26. While contributions are currently modest, we expect the facility to scale meaningfully and emerge as a key growth driver over the next 12–18 months. In Q3FY26, we acquired Zoraya Pharmaceuticals as a step-down subsidiary to strengthen our U.S. marketing and distribution capabilities, enabling direct commercialization of strategic pharmaceutical products in the market. In April 2026, we entered into a joint venture, Amerisyn, marking a key milestone for our U.S. operations and enabling entry into the high-entry-barrier U.S. government procurement market, including federal, veterans affairs, and military supply programs. Our Emerging Markets business is on a steady trajectory as well. With the shift towards niche products, we are now at mid teens EBITDA Margin. Importantly, the Emerging Markets business is now cash flow positive. All in all, we continue to outperform on our stated commitments despite an uncertain environment, reflecting the strength of our long-term strategy, diversified business verticals and disciplined execution. We remain confident in sustaining this momentum in the years ahead, led by robust product pipeline, expanded manufacturing capacities, and a strengthened R&D; infrastructure.” परिणाम PDF

• ट्रेंडलाइन
• 1 महीने पहले

Stocks to buy: Aakash Shah of Choice Broking suggests buying Apollo Hopsitals, Senores Pharma and one other stock; here's why

• बिज़नेस स्टैंडर्ड
• 1 महीने 1 सप्ताह पहले

Senores reported a consolidated revenue of 175 crore, a 64 per cent growth year-on-year increase

• बिज़नेस लाइन
• 5 महीने पहले